Once-Weekly Epoetin Alfa Improves Anemia and Facilitates Maintenance of Ribavirin Dosing in Hepatitis C Virus-Infected Patients Receiving Ribavirin Plus Interferon Alfa

American Journal of Gastroenterology

Volumn 98, Issue 11, 2003, Pages 2491-2499

  Dieterich, Douglas T ^a   Wasserman, Ronald ^b   Bräu, Norbert ^b   Hassanein, Tarek I ^b   Bini, Edmund J ^b   Bowers, Peter J ^b   Sulkowski, Mark S ^b  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

REBETRON; RECOMBINANT ERYTHROPOIETIN;

ABDOMINAL PAIN; ADULT; AGED; ALOPECIA; ANEMIA; ANOREXIA; ARTHRALGIA; ARTICLE; BACKACHE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DEPRESSION; DIARRHEA; DOSE RESPONSE; DRUG DOSE REDUCTION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG ERUPTION; DRUG FEVER; DRUG SAFETY; DRUG TOLERANCE; DRUG WITHDRAWAL; DRY SKIN; DYSPNEA; FATIGUE; FEMALE; HEADACHE; HEMOGLOBIN DETERMINATION; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; INSOMNIA; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; MYALGIA; NAUSEA; NERVOUSNESS; PAIN; PRIORITY JOURNAL; PRURITUS; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SKIN DISEASE; TRANSFUSION; VERTIGO;

EID: 0242437747     PISSN: 00029270     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjgastroenterol.2003.08.006     Document Type: Article

References (37)

1. McHutchison JG, Gordon SC, Schiff ER, et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. N Engl J Med 1998;339:1485-92.
2. Poynard T, Marcellin P, Lee SS, et al. Randomised trial of interferon α2b plus ribavirin for 48 weeks or for 24 weeks versus interferon α2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. Lancet 1998;352: 1426-32.
3. Reichard O, Norkrans G, Frydén A, et al. Randomised, double-blind, placebo-controlled trial of interferon α-2b with and without ribavirin for chronic hepatitis C. Lancet 1998;351: 83-7.
4. Davis GL, Esteban-Mur R, Rustgi V, et al. Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. N Engl J Med 1998;339: 1493-9.
5. Schvarcz R, Ando Y, Sönnerborg A, et al. Combination treatment with interferon alfa-2b and ribavirin for chronic hepatitis C in patients who have failed to achieve sustained response to interferon alone: Swedish experience. J Hepatol 1995;23:17-21.
6. Barbaro G, Di Lorenzo G, Belloni G, et al. Interferon alpha-2b and ribavirin in combination for patients with chronic hepatitis C who failed to respond to, or relapsed after, interferon alpha therapy: A randomized trial. Am J Med 1999;107:112-8.
7. Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: A randomised trial. Lancet 2001;358:958-65.
8. Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002;347:975-82.
9. Schering Corporation. Intron A (interferon alfa-2b, recombinant for injection) prescribing information. Kenilworth, NJ: Schering Corporation, February, 2001.
10. Bodenheimer HC Jr, Lindsay KL, Davis GL, et al. Tolerance and efficacy of oral ribavirin treatment of chronic hepatitis C: A multicenter trial. Hepatology 1997;26:473-7.
11. De Franchesci L, Fattovich G, Turrini F, et al. Hemolytic anemia induced by ribavirin therapy in patients with chronic hepatitis C virus infection: Role of membrane oxidative damage. Hepatology 2000;31:997-1004.
12. Sulkowski MS, Wasserman R, Brooks L, et al. Changes in hemoglobin during therapy with interferon alfa-2b plus ribavirin combination therapy for chronic hepatitis C virus infection. J Viral Hepatitis (in press).
13. Rendo P, Rosso A, Gómez F, et al. Anemia in patients with chronic hepatitis C treated with ribavirin and interferon. Antiviral Therapy 2000;5(suppl 1):C.96 (abstract).
14. Schering Corporation. Rebetron (combination therapy containing Rebetol [ribavirin, USP] capsules and Intron A [interferon alfa-2b, recombinant injection]) prescribing information. Kenilworth, NJ: Schering Corporation, January, 2001.
15. McHutchison JG, Poynard T, Harvey J, et al. The effect of dose reduction on sustained response in patients with chronic hepatitis C receiving interferon alfa-2b in combination with ribavirin. Hepatology 2000;32(4 pt 2):249 (abstract).
16. Jen JF, Glue P, Gupta S, et al. Population pharmacokinetic and pharmacodynamic analysis of ribavirin in patients with chronic hepatitis C. Ther Drug Monit 2000;22:555-65.
17. Hadziyannis SJ, Cheinquer H, Morgan T, et al. Peginterferon alfa-2a (40 kd) (Pegasys) in combination with ribavirin (RBV). Efficacy and safety results from a phase III, randomized, double-blind, multicentre study examining effect of duration of treatment and RBV dose. J Hepatol 2002;36(suppl 1):3 (abstract).
18. Talal AH, Weisz K, Hau T, et al. A preliminary study of erythropoietin for anemia associated with ribavirin and interferon-α. Am J Gastroenterol 2001;96:2802-4 (letter).
19. Dieterich D, Weisz K, Goldman D, et al. Interferon (IFN) and ribavirin (RBV) therapy for hepatitis C (HCV) in HIV-coinfected patients. In: Program and abstracts of the 39th Interscience Conference on Antimicrobial Agents and Chemotherapy (San Francisco, CA). Washington, DC: American Society for Microbiology, 1999:415 (abstract).
20. Crawford J, Cella D, Cleeland CS, et al. Relationship between changes in hemoglobin level and quality of life during chemotherapy in anemic cancer patients receiving epoetin alfa therapy. Cancer 2002;95:888-95.
21. Glaspy J, Bukowski R, Steinberg D, et al. Impact of therapy with epoetin alfa on clinical outcomes in patients with nonmyeloid malignancies during cancer chemotherapy in community oncology practice. J Clin Oncol 1997;15:1218-34.
22. Demetri GD, Kris M, Wade J, et al. Quality-of-life benefit in chemotherapy patients treated with epoetin alfa is independent of disease response or tumor type: Results from a prospective community oncology study. J Clin Oncol 1998;16:3412-25.
23. Gabrilove JL, Cleeland CS, Livingston RB, et al. Clinical evaluation of once-weekly dosing of epoetin alfa in chemotherapy patients: Improvements in hemoglobin and quality of life similar to three-times-weekly dosing. J Clin Oncol 2001; 19:2875-82.
24. Grossman H, Goon B, Bowers P, et al. Once-weekly epoetin alfa dosing is as effective as three-times-weekly dosing in increasing hemoglobin levels and is associated with improved quality of life in anemic, HIV-infected patients. The 010 Study Group. J AIDS (in press).
25. Ware JE, Kosinski M, Keller SD. SF-12: How to score the SF-12 Physical and Mental Health Summary Scales. Boston, MA: The Health Institute, 1995.
26. Gough IR, Furnival CM, Schilder K, et al. Assessment of quality of life of patients with advanced cancer. Eur J Cancer Clin Oncol 1983;19:1161-5.
27. Lydick E, Epstein RS. Interpretation of quality of life changes. Qual Life Res 1993;2:221-6.
28. Casadevall N, Nataf J, Viron B, et al. Pure red-cell aplasia and antierythropoietin antibodies in patients treated with recombinant erythropoietin. N Engl J Med 2002;346:469-75.
29. Casadevall N. Antibodies against rHuEPO: Native and recombinant. Nephrol Dial Transplant 2002;17(suppl 5):42-7 (letter).
30. Weisz KB, Braun JF, Dieterich DT, et al. Erythropoietin use for ribavirin/interferon-induced anemia in hepatitis C patients. In: Programs and abstracts of the 38th Interscience Conference on Antimicrobial Agents and Chemotherapy (San Diego, CA). Washington, DC: American Society for Microbiology 1998: 359 (abstract).
31. Abrams DI, Steinhart C, Franscino R. Epoetin alfa therapy for anaemia in HIV-infected patients: Impact on quality of life. Int J STD AIDS 2000;11:659-65.
32. Brass CA, Piken E. Do antioxidants ameliorate ribavirin induced anemia in HCV patients? Gastroenterology 1999;116(4 pt 2):A1192-3 (abstract).
33. Saeian K, Franco J, Knox J, et al. Does high dose vitamin E supplementation diminish ribavirin-associated hemolysis? An interim report. Hepatology 2001;34(4 pt 2):607A (abstract).
34. Torres MA. Vitamins C and E as protective agents against ribavirin-related anemia in patients with chronic hepatitis C. Gastroenterology 2002;122(4 suppl 1):A-306 (abstract).
35. Sullivan PS, Hanson DL, Chu SY, et al. Epidemiology of anemia in human immunodeficiency virus (HIV)-infected persons: Results from the Multistate Adult and Adolescent Spectrum of HIV Disease Surveillance Project. Blood 1998;91: 301-8.
36. Moore RD, Keruly JC, Chaisson RE. Anemia and survival in HIV infection. J Acquir Immune Defic Syndr Hum Retrovirol 1998;19:29-33.
37. Moore RD. Anemia and human immunodeficiency virus disease in the era of highly active antiretroviral therapy. Semin Hematol 2000;37(suppl 6):18-23.